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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Hindi language. 
The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 275 JIA patients (28.4% systemic, 10.9% oligoarticular, 13.8% RF negative polyarthritis, 
46.9% other categories) and 98 healthy children were enrolled in three centres. The JAMAR components discriminated 
well healthy subjects from JIA patients. Notably, there is no significant difference between the healthy subjects and their 
affected peers in the school-related problems variable. All JAMAR components revealed good psychometric performances. 
In conclusion, the Hindi version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use 
both in routine clinical practice and clinical research.
Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR
Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Hindi parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Hindi language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from February 2012 
to February 2014. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections.
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (five 
items each) and a total score. The four-point Lik-
ert response, referring to the prior month, is ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. For the 
Hindi version of JAMAR, cross-cultural adaptation of the 
standard English version was performed. Reading compre-
hension and understanding of the translated questionnaires 
were tested in a probe sample of ten JIA parents and ten 
patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption (mean and standard deviation [SD] equivalence); 
the second Likert assumption or equal item–scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
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of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Quantitative data were reported as medians 
with 1st and 3rd quartiles and categorical data as absolute 
frequencies and percentages.
The complete Hindi parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Hindi JAMAR was fully cross-culturally adapted from 
the standard English version with two forward and two back-
ward translations with a concordance for 110/123 transla-
tions lines (89.4%) for the parent version and 107/120 lines 
(89.2%) for the child version.
Of the 123 lines in the parent version of the JAMAR, 
122 (99.2%) were understood by at least 80% of the ten 
parents tested (median = 100%; range 50–100%). In the 
patient version of the JAMAR, 113/120 (94.2%) lines were 
understood by at least 80% of the children (median = 100%; 
range 60–100%). Line 19 of the parent JAMAR and lines 
17, 51, 71, 101, 108, 115 and 117 of the child JAMAR were 
modified according to parent’s and patients suggestions, 
respectively.
Demographic and clinical characteristics 
of the subjects
A total of 275 JIA patients and 100 healthy children (total 
of 375 subjects) were enrolled at three paediatric rheumatol-
ogy centres. Two healthy children did not give the consent 
to use their data.
In the 275 JIA subjects, the JIA categories were 28.4% 
with systemic arthritis, 10.9% with oligoarthritis, 13.8% 
with RF negative polyarthritis, 6.9% with RF positive pol-
yarthritis, 1.8% with psoriatic arthritis, 32.0% with enthesi-
tis-related arthritis and 6.2% with undifferentiated arthritis 
(Table 1).
A total of 370/373 (99.2%) subjects had the parent ver-
sion of the JAMAR completed by a parent (272 from parents 
of JIA patients and 98 from parents of healthy children). The 
JAMAR was completed by 162/370 (43.8%) mothers and 
208/370 (56.2%) fathers. The child version of the JAMAR 
was completed by 259/373 (69.4%) children age 7.6 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients. Notably, there is no sig-
nificant difference between the healthy subjects and their 
affected peers in the school-related problems.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items, 
whereas a reduced number of response choices were used 
for PF item 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items (data 
not shown). The median number of items marked as not 
applicable was 1.0% (0–1.0%) for the PF and 3.0% (2–6.0%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 81.3% (73.2–87.5%) for the 
PF items, 61.0% (52.9–62.9%) for the HRQoL PhH items, 
and 78.7% (68.4–81.3%) for the HRQoL PsH items. The 
median ceiling effect was 1.1% (0.7–2.6%) for the PF 
items, 4.0% (3.7–6.6%) for the HRQoL PhH items, and 
1.5% (1.1–1.5%) for the HRQoL PsH items. The median 
floor effect was 40.8% for the pain VAS, 38.6% for the 
disease activity VAS and 35.7% for the well-being VAS. 
The median ceiling effect was 1.1% for the pain VAS, 
1.1% for the disease activity VAS and 0.4% for the well-
being VAS.
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Equal item–scale correlations (second Likert 
assumption)
Pearson item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93.3% of the 
PF items, with the exception of PF item 15, and for 100% of 
the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson item–scale correlations were ≥ 0.4 for 93.3% of 
items of the PF (except for PF item 15) and 100% of items 
of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child versions of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 272/370 Child N = 163/259
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 81.3% 81.0%
 HRQoL PhH 61.0% 57.7%
 HRQoL PsH 78.7% 74.2%
 Pain VAS 40.8% 33.1%
 Disease activity VAS 38.6% 31.9%
 Well-being VAS 35.7% 33.1%
Ceiling effect, median
 PF 1.1% 0.6%
 HRQoL PhH 4.0% 5.5%
 HRQoL PsH 1.5% 1.8%
 Pain VAS 1.1% 2.4%
 Disease activity VAS 1.1% 1.2%
 Well-being VAS 0.4% 1.2%
Items with equivalent item–scale correlation 93% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Items with item–scale correlation ≥ 0.4 93% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.88 0.86
 PF-HW 0.88 0.88
 PF-US 0.75 0.76
 HRQoL PhH 0.87 0.88
 HRQoL PsH 0.82 0.81
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.72 0.90
 HRQoL PhH 0.09 0.85
 HRQoL PsH 0.58 0.81
Spearman correlation with JIA core set variables, median
 PF 0.6 0.7
 HRQoL PhH 0.6 0.7
 HRQoL PsH 0.4 0.5
 Pain VAS 0.5 0.5
 Disease activity VAS 0.5 0.4
 Well-being VAS 0.5 0.5
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.88 for PF-LL, 0.88 for PF-HW, 0.75 
for PF-US. Cronbach’s alpha was 0.87 for HRQoL PhH and 
0.82 for HRQoL PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 18 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 7 days (6–8 days). The intraclass corre-
lation coefficients (ICC) for the PF total score showed a 
substantial reproducibility (ICC = 0.72). The ICC for the 
HRQoL PhH showed a poor reproducibility (ICC = 0.09) 
and for the HRQoL PsH showed a moderate reproducibility 
(ICC = 0.58).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.5 to 0.7 
(median = 0.6). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.7, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.5 to 0.7 (median = 0.6), whereas for the PsH ranged from 
0.2 to 0.5 (median = 0.4). The PhH and the PsH showed the 
best correlation with the parent global assessment of well-
being (r = 0.7, p < 0.001 and r = 0.6, p < 0.001, respectively). 
The median correlations between the pain VAS, the well-
being VAS, and the disease activity VAS and the physician-
centred and laboratory measures were 0.5 (0.4–0.6), 0.5 
(0.4–0.5), 0.5 (0.4–0.5), respectively.
Discussion
In this study, the Hindi version of the JAMAR was cross-
culturally adapted from the original standard English version 
with two forward and two backward translations. According 
to the results of the validation analysis, the Hindi parent and 
patient versions of the JAMAR possess satisfactory psycho-
metric properties. The disease-specific components of the 
questionnaire discriminated well between patients with JIA 
and healthy controls. Notably, there was no significant differ-
ence between the healthy subjects and their affected peers in 
the school-related problems variable. This finding indicates 
that children with JIA adapt well to the consequences of 
JIA. The functional ability questionnaire PF revealed to be 
able to discriminate between the different JIA subtypes with 
the children diagnosed with undifferentiated arthritis hav-
ing a higher degree of disability. Psychometric evaluation 
was good for all domains with few exceptions: PF item 15 
(bite a sandwich or an apple) showing a lower Items internal 
consistency. However, the overall internal consistency was 
good for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents.
The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care. In conclusion, 
the Hindi version of the JAMAR was found to have satisfac-
tory psychometric properties and it is, thus, a reliable and 
valid tool for the multidimensional assessment of children 
with JIA.
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